NCT02683785 - A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2016

Primary Completion Date

November 29, 2017

Study Completion Date

November 29, 2017

Conditions

Osteoarthritis

Interventions

DRUG

GSK3196165

GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.

DRUG

Placebo

Matching placebo will be administered as above.

Trial Locations (16)

16635

GSK Investigational Site, Duncansville

24768

GSK Investigational Site, Rendsburg

33015

GSK Investigational Site, Miami

36043

GSK Investigational Site, Fulda

91054

GSK Investigational Site, Erlangen

7511JX

GSK Investigational Site, Enschede

3015 CE

GSK Investigational Site, Rotterdam

8601 ZK

GSK Investigational Site, Sneek

15-879

GSK Investigational Site, Bialystok

67-100

GSK Investigational Site, Nowa Sól

00-660

GSK Investigational Site, Warsaw

03-291

GSK Investigational Site, Warsaw

CT1 3NG

GSK Investigational Site, Canterbury

DE22 3NE

GSK Investigational Site, Derby

NE298NH

GSK Investigational Site, North Shields

YO31 8HE

GSK Investigational Site, York